受强制性开放获取政策约束的文章 - Claire Verschraegen了解详情
可在其他位置公开访问的文章：34 篇
Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies
YZ Jiang, D Ma, C Suo, J Shi, M Xue, X Hu, Y Xiao, KD Yu, YR Liu, Y Yu, ...
Cancer cell 35 (3), 428-440. e5, 2019
强制性开放获取政策： 国家自然科学基金委员会
GPR30 predicts poor survival for ovarian cancer
HO Smith, H Arias-Pulido, DY Kuo, T Howard, CR Qualls, SJ Lee, ...
Gynecologic oncology 114 (3), 465-471, 2009
强制性开放获取政策： US National Institutes of Health
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
YZ Jiang, Y Liu, Y Xiao, X Hu, L Jiang, WJ Zuo, D Ma, J Ding, X Zhu, J Zou, ...
Cell research 31 (2), 178-186, 2021
强制性开放获取政策： 国家自然科学基金委员会
Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005
Y Ji, C Rankin, S Grunberg, AE Sherrod, J Ahmadi, JJ Townsend, ...
Journal of Clinical Oncology 33 (34), 4093-4098, 2015
强制性开放获取政策： US National Institutes of Health
Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial
R Hassan, A Thomas, JJ Nemunaitis, MR Patel, J Bennouna, FL Chen, ...
JAMA oncology 5 (3), 351-357, 2019
强制性开放获取政策： US National Institutes of Health
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas
BT Mossman, A Shukla, NH Heintz, CF Verschraegen, A Thomas, ...
The American journal of pathology 182 (4), 1065-1077, 2013
强制性开放获取政策： US National Institutes of Health
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer
H Arias-Pulido, M Royce, Y Gong, N Joste, L Lomo, SJ Lee, N Chaher, ...
Breast cancer research and treatment 123, 51-58, 2010
强制性开放获取政策： US National Institutes of Health
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
M Li, D Spakowicz, J Burkart, S Patel, M Husain, K He, EM Bertino, ...
Journal of Cancer Research and Clinical Oncology 145, 2541-2546, 2019
强制性开放获取政策： US National Institutes of Health
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509
LL Garland, K Chansky, AJ Wozniak, AS Tsao, SM Gadgeel, ...
Journal of Thoracic Oncology 6 (11), 1938-1945, 2011
强制性开放获取政策： US National Institutes of Health
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
S Kim, E Wuthrick, D Blakaj, Z Eroglu, C Verschraegen, R Thapa, M Mills, ...
The Lancet 400 (10357), 1008-1019, 2022
强制性开放获取政策： US National Institutes of Health
Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors
H Arias-Pulido, HO Smith, NE Joste, T Bocklage, CR Qualls, A Chavez, ...
Gynecologic oncology 114 (3), 480-485, 2009
强制性开放获取政策： US National Institutes of Health
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
JJ Luke, SA Piha-Paul, T Medina, CF Verschraegen, M Varterasian, ...
Clinical Cancer Research 29 (13), 2435-2444, 2023
强制性开放获取政策： US National Institutes of Health
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
D Spakowicz, R Hoyd, M Muniak, M Husain, JS Bassett, L Wang, ...
BMC cancer 20, 1-13, 2020
强制性开放获取政策： US National Institutes of Health
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients
N Chaher, H Arias-Pulido, N Terki, C Qualls, K Bouzid, C Verschraegen, ...
Breast cancer research and treatment 131, 437-444, 2012
强制性开放获取政策： US National Institutes of Health
Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim
J Moukharskaya, DM Abrams, T Ashikaga, F Khan, J Schwartz, K Wilson, ...
Supportive Care in Cancer 24, 3085-3093, 2016
强制性开放获取政策： US National Institutes of Health
Genomic features of rapid versus late relapse in triple negative breast cancer
Y Zhang, S Asad, Z Weber, D Tallman, W Nock, M Wyse, JF Bey, KL Dean, ...
BMC cancer 21 (1), 568, 2021
强制性开放获取政策： US National Institutes of Health, Susan G. Komen
The national clinical trials network: conducting successful clinical trials of new therapies for rare cancers
AF Schott, JJ Welch, CF Verschraegen, R Kurzrock
Seminars in oncology 42 (5), 731-739, 2015
强制性开放获取政策： US National Institutes of Health
DR6 as a diagnostic and predictive biomarker in adult sarcoma
K Yang, C Mooney, G Spahlinger, S Schuetze, H Arias-Pulido, ...
PloS one 7 (5), e36525, 2012
强制性开放获取政策： US National Institutes of Health
A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms
DH Owen, B Benner, L Wei, V Sukrithan, A Goyal, Y Zhou, C Pilcher, ...
Clinical Cancer Research 29 (4), 731-741, 2023
强制性开放获取政策： US National Institutes of Health, LUNGevity Foundation, USA
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
AM Tsimberidou, JV Shaw, D Juric, C Verschraegen, AM Weise, ...
Journal of Hematology & Oncology 14, 1-10, 2021
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定